Gong‐Hao He

Gong‐Hao He

Auto-generated profile, based on publicly available information

Gong‐Hao He

Department of Clinical Pharmacy The 920th Hospital of Joint Logistics Support Force Kunming China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
YFYu‐Xin Fan
Yu‐Xin Fan
JWJiang‐Hai Wu
Jiang‐Hai Wu
SYSun‐Jun Yin
Sun‐Jun Yin
TZTao Zhou
Tao Zhou
YHYan‐Hua Huang
Yan‐Hua Huang
GHGong‐Hao He
Gong‐Hao He

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZLZhi-Ran Li
Zhi-Ran Li
QYQin Yang
Qin Yang
TZTao Zhou
Tao Zhou
YHYan-Hua Huang
Yan-Hua Huang
HZHua-Zhu Zhang
Hua-Zhu Zhang
GHGong-Hao He
Gong-Hao He
Background. Numerous recent studies suggested that overexpression of the long noncoding RNA small nucleolar RNA host gene 12 (SNHG12) exhibited prooncogenic activity in multiple cancers. However, results regarding the prognostic value of SNHG12 in cancers still remained controversial. Therefore, we conducted a meta‐analysis complemented with bioinformatics analysis to elucidate the clinical significance of SNHG12 in cancer patients. Methods. PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang, and Weipu databases were searched for eligible studies until July 2020. Additionally, bioinformatics analysis was applied to verify the results of meta‐analysis. Results. Twenty‐three related studies consisting of 1389 cancer patients were enrolled in the current meta‐analysis. Elevated SNHG12 expression was found to be significantly associated with poor overall survival (OS) (HR = 1.81; 95% CI: 1.53‐2.13; P < 0.001) and disease‐free survival (DFS) (HR = 1.40; 95% CI: 1.12‐1.76; P = 0.004) in multiple cancers, which were also verified by the results of bioinformatics analysis. Moreover, overexpression of SNHG12 was also related to clinicopathological characteristics including LNM, distant metastasis, high clinical stage, large tumor size, and poor tumor differentiation in diverse types of cancers. Conclusion. The present findings indicated that SNHG12 might act as a novel biomarker for diagnosis or prognosis in human cancers.